Dr. Bender is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
26732 Crown Valley Pkwy Ste 271
Mission Viejo, CA 92691Phone+1 949-427-7933Fax+1 949-715-1273
Education & Training
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1970 - 1972
- David Geffen School of Medicine at UCLAClass of 1970
- University of California, Santa BarbaraB.A., Biology, With High Honors, 1966
- University of California, Santa BarbaraBA, Biology, with High Honors, 1966
Certifications & Licensure
- CA State Medical License 1971 - 2026
- AZ State Medical License 2005 - 2022
- NE State Medical License 2005 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Medical Intern of the Year 1971
- Regents Scholar State of California, 1966
- Alpha Omega Alpha Medical Honor Society
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsMolecular Classification of Unknown Primary CancerRichard A. Bender, Mark G. Erlander
Seminars in Oncology. 2009-02-01 - 48 citationsDistribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.J. Liu, Kevin Qu, Anthony Sferruzza, Richard A. Bender
Anti-Cancer Drugs. 2007-07-01 - 186 citationsThe HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast CancerXiao-Jun Ma, Susan G. Hilsenbeck, Wilson Wang, Li Ding, Dennis C. Sgroi
Journal of Clinical Oncology. 2006-10-01
Journal Articles
- "Molecular Identification of Carcinoma of Unknown Primary (CUP) with Gene Expression Profiling"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- "Preliminary Study of Three Tumor Markers for Hepatocellular Carcinoma: AFP, AFP-L3 and Glypican-3"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- "A Multiplex Assay for Detection of Common Pediatric Sarcoma Tumor Markers"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- Join now to see all
Abstracts/Posters
- Personalized Treatment of Advanced Metastatic Breast Cancer (MBC) Utilizing Target Now in a Community- Based Oncology PracticeLoesch D, Waisman J, Link J, Alarcon A, Boehm K, Ghazadpour A and Bender R,, San Antonio Breast Cancer Symposium, 12/7/2011
- Differences in gene expression between primary chemotherapy-naïve prostate carcinomas and hormone-refractory prostate carcinomasBasu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference, San Francisco, 11/16/2011
- Differences in gene expression between primary chemotherapy-naive prostate carcinomas and hormone-refractory prostate carcinomasBasu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference on “Molecular Targets and Cancer Therapeutics", 11/12/2011
- Join now to see all
Press Mentions
- Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingDecember 8th, 2022
- Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory BoardOctober 18th, 2022
- Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell(R)November 29th, 2016
- Join now to see all
Professional Memberships
- Member
- Fellow
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: